Market Capitalization

GoldMining Inc. renews its flexible financing tool to tap the market. We analyze the strategy, the projects at stake, and the dilution dilemma for investors.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

Alerus Financial’s 5% dividend increase isn’t just a payout; it’s a story of strategic diversification and resilience in a volatile banking sector.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

SoFi's surprise $1.5 billion stock sale sends shares tumbling. Is this a bold play for market dominance or a sign of fintech's increasing capital hunger?

A promising fintech's complex arbitrage strategy collapses, triggering a stock crash, CEO exit, and a wave of securities fraud investigations.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.